Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
HPTX > SEC Filings for HPTX > Form 8-K on 3-Jun-2013All Recent SEC Filings

Show all filings for HYPERION THERAPEUTICS INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for HYPERION THERAPEUTICS INC


3-Jun-2013

Completion of Acquisition or Disposition of Assets, Submission of Matte


Item 2.01. Completion of Acquisition or Disposition of Assets.

On May 31, 2013, Hyperion Therapeutics, Inc. (the "Company") completed its acquisition of BUPHENYLŪ (sodium phenylbutyrate) Tablets and Powder, an FDA-approved therapy for treatment of the most prevalent urea cycle disorders ("UCD"), from Ucyclyd Pharma, Inc. ("Ucyclyd"), a subsidiary of Valeant Pharmaceuticals International, Inc. The Company received a net payment of $11 million from Ucyclyd at closing, which represents the $19 million purchase price for BUPHENYL due to Ucyclyd and a $32 million payment due to the Company as a result of Ucyclyd 's exercise of its option to retain AMMONULŪ(sodium phenylacetate and sodium benzoate) Injection 10%/10%, a hospital-based product used for the treatment of acute hyperammonemia in UCD patients, less costs of approximately $2 million in finished goods and active pharmaceutical ingredient due to Ucyclyd. The Company is obligated to pay subsequent milestone and royalty payments to Ucyclyd.

As previously announced, the Company exercised its right to acquire BUPHENYL and AMMONUL on April 29, 2013, pursuant to an Amended and Restated Collaboration Agreement between the Company and Ucyclyd, dated March 22, 2012 (the "Collaboration Agreement"). On May 17, 2013, Ucyclyd exercised its option to retain the rights to AMMONUL pursuant to the Collaboration Agreement.



Item 5.07. Submission of Matters to a Vote of Security Holders.

The Company held its 2013 Annual Meeting of Stockholders (the "Annual Meeting") on May 29, 2013. There were 20,010,416 shares of common stock eligible to be voted at the Annual Meeting and 18,472,931 shares of common stock were presented in person or represented by proxy at the Annual Meeting, which constituted a quorum to conduct business.

There were two proposals submitted to the Company's stockholders at the Annual Meeting. All proposals were passed. The final results of voting on each of the proposals are as follows:

Proposal 1: Election of Directors

    Nominee                    Votes For        Votes Withheld       Broker Non-Vote
    Bijan Salehizadeh, M.D.     14,849,970            1,724,715             1,898,246
    Donald J. Santel            14,857,482            1,717,203             1,898,246

Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm

Votes For Votes Against Abstain Broker Non-Vote 18,471,389 1,542 0 -



Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

                   Exhibit
                   Number    Description

                   99.1      Press Release, dated June 3, 2013.


  Add HPTX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for HPTX - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.